The European Hematology Association (EHA)

Research

Highlights from the SWG

Events

Participation in the 19th European LeukemiaNet (ELN) Symposium

Location and date

This event was held in Mannheim, Germany, on April 18, 2023.

Chairs

  • D. Hoelzer
  • S. Chiaretti

Topics

  • Blinatumomab Frontline HOVON Trial (A. Rijneveld, Netherlands).
  • Inotuzumab ozogamicin in MRD+ ALL (G. Marconi, Italy).
  • Blina-Venetoclax in R/R or MRD+ ALL (C. Baldus, Germany).
  • Real-life use of Venetoclax-Navitoclax (F. Malfona, Italy).
  • Update of the D-ALBA Trial (S. Chiaretti, Italy).
  • Allo-SCT in CR1, part. in Ph+/Ph-like ALL (J. Ribera, Spain).
  • Progress on T-ALL: GMALL Experience (N. Gökbuget, Germany).

EWALL Meeting

Location and date

This event was held in Krakow, Poland, on June 23–24, 2023.

Chairs

  • Sebastian Giebel
  • Anna Czyżs

Program—Friday, June 23, 2023

15:00–15:10
Welcome Day 1 (Sebastian Giebel, Poland).

15:10–15:30
EWALL Organization Issues (chair: Adele Fielding).

15:30–17:00
National adult ALL studies (chair: Sebastian Giebel, Poland):

  • Upfront Blinatumomab in First Line Therapy of ALL – First Results of Phase 2 HOVON 146 Study (Anita Rijneveld, Holland)
  • Frontline Consolidation with Blinatumomab for High-Risk Ph(-) ALL. Update of the Graall-2014-QUEST study (Nicolas Boissel, France)
  • UKALL60+ trial in older persons (Adele Fielding, UK)
  • Obinutuzumab versus Rituximab for adults with ALL (OVERALL PALG ALL7 trial) (Sebastian Giebel, Poland)
  • Impact of dose modifications of PEG Asparaginase on the results of the ALL2019 trial. Interim analysis (Anna Torrent, Spain)
  • Analysis of MRD-oriented alloHSCT vs. early alloHSCT for adult KMT2A ALL (Jordi Ribera, Spain)
  • Comparison of results of ALLHR 03+ALLHR11 trials vs. those of ALL2019 trial on T-ALL according to RAS mutations (Eulalia Genescà, Spain)

17:15–18:15
Ongoing and Future Collaborative Projects (chair: Philippe Rousselot):

  • New EWALL INO2 proposal (Philippe Rousselot, France)
  • Status of the HARMONY & HARMONY+ Projects (Jordi Ribera, Spain)
  • Brexucabtagene autoleucel for the treatment of adults with R/R ALL. Experience from clinical practice (panel discussion)

Program—Saturday, June 24, 2023

08:50–09:00
Welcome Day 2 (Anna Czyż, Poland).

09:00–10:15
R/R ALL - approaches to personalized treatment (chair: Adele Fielding):

  • Personalized treatment of R/R B-ALL using gilteritinib, everolimus or trametinib + dexamethasone. PALG GET-DEX study. (Ewa Lech-Marańda, Poland)
  • R/R T-ALL based on oncogenetic, drug testing, and targeted therapy: ALL-TARGET (Philippe Rousselot, France)
  • Ser/Thr and Tyr kinase activity profiling and panel RNA sequencing to drive treatment decisions in ALL. (Eliza Głodkowska-Mrówka, Poland)

10:30–11:30
Miscellaneous (chair: Anna Czyż, Poland):

  • GRAALL-2014 trial aiming at reducing TRM and alloHSCT based on early MRD (Nicolas Boissel, France)
  • Recent EBMT studies on alloHCT in ALL (Sebastian Giebel, Poland)

Advancements

  • Incorporation of immunotherapy in frontline therapy of adult ALL in national and in an EWALL-initiated phase 3 trial (ACCADEMIA, in preparation).
  • Multicenter EWALL phase 3 trials for adults with newly diagnosed B-cell precursor ALL and T-ALL (under development).
  • Development of an EWALL guideline for diagnosis and management of adult ALL (manuscript accepted in Blood).

Forthcoming activities

  • Development of a phase 3 trial incorporating blinatumomab in first-line therapy for young adults (18-60 yr) with Ph-negative ALL.
  • Development of a pragmatic trial for R/R T-ALL.
  • Development of a phase 3 trial incorporating BH3 mimetics in newly diagnosed young adults (18-60 yr) with T-ALL.